Preventing and Treating Brain Metastases with Three First-Line EGFR-TKI in Patients with EGFR Mutation Advanced NSCLC

被引：0
|
作者：
Lin, C. [1 ]
Su, W. [1 ]
Wu, Y. [2 ]
机构：
[1] Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan, Taiwan
[2] Natl Cheng Kung Univ Hosp, Dept Nursing, Tainan, Taiwan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
Brain metastasis; tyrosine kinase inhibitor; EGFR mutation;
D O I：
10.1016/j.jtho.2018.08.616
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.01-60
引用
收藏
页码：S484 / S484
页数：1
相关论文
共 50 条
  • [41] Efficacy of immune checkpoint inhibitor therapy in EGFR mutation-positive patients with NSCLC and brain metastases who have failed EGFR-TKI therapy
    Zhou, Shujie
    Ren, Fei
    Meng, Xiangjiao
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [42] Oral Vinorelbine Monotherapy in Patients with EGFR plus NSCLC after Failure of EGFR-TKI in First Line: A Prospective Study
    Kowalski, Dariusz
    Banna, Giuseppe Luigi
    Ramlau, Rodryg
    Ceresoli, Giovanni
    Camerini, Andrea
    Milanowski, Janusz
    Caruso, Michele
    Landreau, Philippe
    Vedovato, Jean-Claude
    Tang, Eng Huat
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1217 - S1218
  • [43] Concurrent Brain Radiotherapy and EGFR-TKI Have Better Survival Benefits in Patients with Brain Metastases from EGFR-Mutant NSCLC
    Zhu, Y.
    Chen, Y.
    Han, S.
    Ying, X.
    Sun, X.
    Xu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S502 - S502
  • [44] Experimental study of EGFR-TKI aumolertinib combined with ionizing radiation in EGFR mutated NSCLC brain metastases tumor
    Zhang, Yaoshuai
    Li, Yongping
    Han, Yuehua
    Li, Min
    Li, Xian
    Fan, Fangtian
    Liu, Hao
    Li, Shanshan
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2023, 945
  • [45] EGFR-TKI Combined with Pemetrexed versus EGFR-TKI Monotherapy in Advanced EGFR-Mutated NSCLC: A Prospective, Randomized, Exploratory Study
    Gu, Weiguang
    Zhang, Hua
    Lu, Yiyu
    Li, Minjing
    Yang, Shuang
    Liang, Jianmiao
    Ye, Zhijian
    Li, Zhihua
    He, Minhong
    Shi, Xiaoliang
    Wang, Fei
    You, Dong
    Gu, Weiquan
    Feng, Weineng
    CANCER RESEARCH AND TREATMENT, 2023, 55 (03): : 841 - 850
  • [46] Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases
    Ke, Shao-bo
    Qiu, Hu
    Chen, Jia-mei
    Shi, Wei
    Chen, Yong-shun
    CURRENT MEDICAL SCIENCE, 2018, 38 (06) : 1062 - 1068
  • [47] Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): final overall survival analysis
    Bischoff, H.
    Bohnet, S.
    Reinmuth, N.
    Rueckert, A.
    zum Buschenfelde, Meyer C.
    Hodge, R.
    Rukazenkov, Y.
    Ramalingam, S. S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 77 - 77
  • [48] Therapeutic Effect of First-line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI) Combined with Whole Brain Radiotherapy on Patients with EGFR Mutation-positive Lung Adenocarcinoma and Brain Metastases
    Shao-bo Ke
    Hu Qiu
    Jia-mei Chen
    Wei Shi
    Yong-shun Chen
    Current Medical Science, 2018, 38 : 1062 - 1068
  • [49] Impact of heavy smoking on the benefits from first-line EGFR-TKI therapy in patients with advanced lung adenocarcinoma
    Zhang, Ping
    Nie, Xin
    Bie, Zhixin
    Li, Lin
    MEDICINE, 2018, 97 (09)
  • [50] Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFRm advanced NSCLC (FLAURA): Final overall survival analysis
    Ramalingam, S. S.
    Gray, J. E.
    Ohe, Y.
    Cho, B. C.
    Vansteenkiste, J.
    Zhou, C.
    Reungwetwattana, T.
    Cheng, Y.
    Chewaskulyong, B.
    Shah, R.
    Lee, K. H.
    Cheema, P.
    Tiseo, M.
    John, T.
    Lin, M. C.
    Imamura, F.
    Hodge, R.
    Rukazenkov, Y.
    Soria, J-C.
    Planchard, D.
    ANNALS OF ONCOLOGY, 2019, 30 : 914 - +
12345